Vanguard Personalized Indexing Management LLC Has $2.02 Million Stake in Hologic, Inc. $HOLX

Vanguard Personalized Indexing Management LLC grew its position in Hologic, Inc. (NASDAQ:HOLX) by 82.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,917 shares of the medical equipment provider’s stock after purchasing an additional 14,002 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Hologic were worth $2,015,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Greenleaf Trust raised its holdings in Hologic by 5.1% in the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after acquiring an additional 173 shares during the period. Beverly Hills Private Wealth LLC grew its position in shares of Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 180 shares during the last quarter. Allworth Financial LP increased its stake in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the period. First American Bank lifted its holdings in Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after purchasing an additional 245 shares during the last quarter. Finally, Townsquare Capital LLC boosted its stake in Hologic by 4.5% in the 1st quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider’s stock valued at $418,000 after purchasing an additional 293 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HOLX shares. Mizuho set a $75.00 price objective on Hologic in a research report on Thursday, July 31st. Stephens reiterated an “overweight” rating and issued a $78.00 price objective on shares of Hologic in a research note on Thursday, September 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Hologic in a report on Wednesday, October 8th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $80.15.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $68.50 on Friday. The firm has a 50 day moving average of $67.08 and a 200-day moving average of $63.45. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $15.24 billion, a PE ratio of 28.42, a PEG ratio of 2.30 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period last year, the firm posted $1.06 earnings per share. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.